Your browser doesn't support javascript.
loading
節目: 20 | 50 | 100
结果 1 - 6 de 6
过滤器
添加過濾器








年份範圍
1.
Indian J Ophthalmol ; 2023 Jul; 71(7): 2927
文章 | IMSEAR | ID: sea-225162

摘要

Background: Plaque brachytherapy is an evolving, yet effective globe and vision-sparing modality for the treatment of intraocular tumors by transscleral irradiation of the tumor base with a radioactive implant. The American Brachytherapy Society (ABS) along with the collaboration of the international multicenter Ophthalmic Oncology Task Force (OOTF) was assembled to reach a consensus regarding establishing practice guidelines and setting standards of care for intraocular tumors. The advent of plaque brachytherapy has revolutionized the outcomes of intraocular tumors, thus ensuring globe salvage, reducing morbidity and mortality, and avoiding cosmetic disfigurement. A well-planned dosimetry for plaque brachytherapy results in achieving local tumor control and excellent prognosis. Purpose: This technique provides the advantage of focal radiation, thus eliminating the damage to the adjacent structures, minimal periorbital tissue damage, absence of cosmetic disfigurement owing to lack of retarded bone growth as seen in external beam radiotherapy. Thus, it reduces the risk of metastasis, and with the recent advances, it provides a shorter duration of treatment. Synopsis: In this video, we shall display the concept of plaque brachytherapy, the various types of plaques available, different radiations sources, planning dosimetry and calculations, target disease spectrum, surgical placement, and post-radiation outcomes in terms of local tumor control and prognosis. Highlights: This video highlights the history, basic principles and techniques of plaque brachytherapy and provides an understanding of its applications in the world of ocular oncology.

3.
Indian J Ophthalmol ; 2015 Dec; 63(12): 927-929
文章 在 英语 | IMSEAR | ID: sea-179062

摘要

A 40‑year‑old male presented with an orbital extension of conjunctival squamous cell carcinoma (SCC). The orbital mass was seen protruding outward from the left palpebral fissure overhanging the lower eyelid, completely obscuring the globe and lower lid. The patient gave a history of excision biopsy, which was histopathologically diagnosed as ocular surface squamous neoplasia. He also gave a history of tumor recurrence, which gradually progressed to assume the form of the presently visible orbital mass. Computed tomography of the orbits showed the mass extending into the left orbit causing superior displacement of the globe. After a negative locoregional and systemic metastatic screening, neoadjuvant intravenous systemic chemotherapy with cisplatin and 5‑fluorouracil were initiated in an attempt to reduce the size of the tumor. Three cycles of tri‑weekly chemotherapy resulted in a significant reduction of the orbital tumor size with the globe and the lower lid being visible, thus making a lid‑sparing orbital exenteration possible. The patient subsequently underwent an orbital exenteration and at 6‑month follow‑up, the patient was free from local and regional disease. To our knowledge, this is the first reported case where systemic neoadjuvant chemotherapy has been used to reduce the size of invasive SCC with orbital extension, thereby permitting a lid‑sparing orbital exenteration.

4.
Indian J Ophthalmol ; 2013 July; 61(7): 357-359
文章 在 英语 | IMSEAR | ID: sea-148214

摘要

Retinoblastoma is the most common intraocular malignancy in children, with a reported incidence ranging from 1 in 15,000 to 1 in 18,000 live births. Metastatic retinoblastoma is rare in developed countries, with a reported range from 4.8% in the United States to 5.8% in the United Kingdom. However, the frequency reported from developing countries varies from 9 to 11% at presentation. The mortality is very high owing to late presentations, delayed diagnosis compounded by socio-economic factors. The management of metastatic retinoblastoma is evolving, but it is still a challenge in pediatric oncology. We present a case of an extensive skeletal metastasis that initially presented as a massive orbital retinoblastoma.

5.
Indian J Chest Dis Allied Sci ; 2006 Jan-Mar; 48(1): 67-9
文章 在 英语 | IMSEAR | ID: sea-29734

摘要

Strongyloides stercoralis is a nematode endemic in tropical and subtropical regions. In immunocompetent subjects, pulmonary disease caused by the parasite is unremarkable but the same can be life threatening in immunocompromised subjects. Though described in literature it is rarely seen in Indian subjects. We report a patient with ARDS due to Strongyloides stercoralis complicating non-Hodgkin's lymphoma with neutropenia.


Subject(s)
Aged , Albendazole/therapeutic use , Animals , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antiparasitic Agents/therapeutic use , Cyclophosphamide/adverse effects , Doxorubicin/adverse effects , Fatal Outcome , Humans , Ivermectin/therapeutic use , Lymphoma, Non-Hodgkin/complications , Male , Multiple Organ Failure/etiology , Neutropenia/etiology , Prednisolone/adverse effects , Respiratory Distress Syndrome/etiology , Strongyloides stercoralis/isolation & purification , Strongyloidiasis/complications , Vincristine/adverse effects
搜索明细